Nektar Therapeutics (NKTR) Operating cash flow 2016–2025
Nektar Therapeutics (NKTR) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$208.5MFY2025 · since FY2016: -$117.0M → -$208.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$208.5M | -18.7% |
| FY2024 | -$175.7M | +8.8% |
| FY2023 | -$192.6M | +36.6% |
| FY2022 | -$304.0M | +26.3% |
| FY2021 | -$412.7M | -31.7% |
| FY2020 | -$313.3M | +4.7% |
| FY2019 | -$328.7M | -145.8% |
| FY2018 | $718.2M | +993.1% |
| FY2017 | -$80.4M | +31.3% |
| FY2016 | -$117.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NKTR financial trends
NKTR RevenueNKTR Net incomeNKTR Net marginNKTR Gross profitNKTR Gross marginNKTR Operating incomeNKTR Operating marginNKTR Free cash flowNKTR Capital expendituresNKTR Return on equityNKTR Stock buybacksNKTR Dividends paidNKTR Total assetsNKTR Total liabilitiesNKTR Shareholders’ equityNKTR overview →